Skip to main content

Advertisement

SpringerLink
Log in

Five-year follow-up of a case of lipoprotein glomerulopathy with APOE Kyoto mutation

  • Case Report
  • Published:
CEN Case Reports Aims and scope Submit manuscript

Abstract

We report the case of a 34-year-old Japanese male with lipoprotein glomerulopathy (LPG). Renal biopsy showed LPG, and followed by a genetic analysis revealed a mutation in apolipoprotein E gene (APOE Kyoto; Arg25Cys). We started treatment with probucol, bezafibrate, losartan, and allopurinol. Urinary protein decreased in response to treatment but has remained at about 1.27 ± 0.71 g/gCr, and a repeat biopsy which was performed 1 year after the first biopsy showed no clear evidence of pathological remission and complication of other glomerular disease. After 5 years of follow-up after the start of treatment, renal function has almost maintained without apparent deterioration. Interestingly, the course of the urinary protein level closely paralleled his triglyceride and cholesterol levels in a long-term. This observation suggests the importance of tight control of lipid profiles as a means of renoprotection in LPG patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Saito T, Sato H, Kudo K, et al. Lipoprotein glomerulopathy: glomerular lipoprotein thrombi in a patient with hyperlipoproteinemia. Am J Kidney Dis. 1989;13:148–53.

    Article  CAS  PubMed  Google Scholar 

  2. Ishigaki Y, Oikawa S, Suzuki T, et al. Virus-mediated transduction of apolipoprotein E (ApoE)-sendai develops lipoprotein glomerulopathy in ApoE-deficient mice. J Biol Chem. 2000;275:31269–73.

    Article  CAS  PubMed  Google Scholar 

  3. Russi G, Furci L, Leonelli M, et al. Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced Extracorporeal Lipoprotein Precipitation system): a case report. J Med Case Rep. 2009;3:9311.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Xin Z, Zhihong L, Shijun L, et al. Successful treatment of patients with lipoprotein glomerulopathy by protein A immunoadsorption: a pilot study. Nephrol Dial Transplant. 2009;24:864–9.

    Article  PubMed  Google Scholar 

  5. Toyota K, Hashimoto T, Ogino D, et al. A founder haplotype of APOE-Sendai mutation associated with lipoprotein glomerulopathy. J Hum Genet. 2013;58:254–8.

    Article  CAS  PubMed  Google Scholar 

  6. Hu Z, Huang S, Wu Y, et al. Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation. Kidney Int. 2014;85:416–24.

    Article  CAS  PubMed  Google Scholar 

  7. Ishimura A, Watanabe M, Nakashima H, et al. Lipoprotein glomerulopathy induced by ApoE-Sendai is different from glomerular lesions in aged apoE-deficient mice. Clin Exp Nephrol. 2009;13:430–7.

    Article  PubMed  Google Scholar 

  8. Andrews PA, O’Donnell PJ, Dilly SA, Snowden SA, Bewick M. Recurrence of lipoprotein glomerulopathy after renal transplantation. Nephrol Dial Transplant. 1997;11:2442–4.

    Article  Google Scholar 

  9. Shimizu M, Ohno T, Kimoto H, Hosono S, Nozawa M. A newborn infant with lipoprotein glomerulopathy associated with congenital nephrotic syndrome. Pediatr Int. 2001;43:78–80.

    Article  CAS  PubMed  Google Scholar 

  10. Matsunaga A, Sasaki J, Komatsu T, et al. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy. Kidney Int. 1999;56:421–7.

    Article  CAS  PubMed  Google Scholar 

  11. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232:34–47.

    Article  CAS  PubMed  Google Scholar 

  12. Usui R, Shibuya M, Ishibashi S, Maru Y. Ligand-independent activation of vascular endothelial growth factor receptor 1 by low-density lipoprotein. EMBO Rep. 2007;8:1155–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Cao C, Lawrence DA, Li Y, et al. Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration. EMBO J. 2006;25:1860–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Kanamaru Y, Nakao A, Shirato I, et al. Chronic graft-versus-host autoimmune disease in Fc receptor gamma chain-deficient mice results in lipoprotein glomerulopathy. J Am Soc Nephrol. 2002;13:1527–33.

    Article  CAS  PubMed  Google Scholar 

  15. Ito K, Nakashima H, Watanabe M, Ishimura A, et al. Macrophage impairment produced by Fc receptor gamma deficiency plays a principal role in the development of lipoprotein glomerulopathy in concert with apoE abnormalities. Nephrol Dial Transplant. 2012;27:3899–907.

    Article  CAS  PubMed  Google Scholar 

  16. Saito T, Matsunaga A, Oikawa S. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis. 2006;47:199–211.

    Article  CAS  PubMed  Google Scholar 

  17. Matsunaga A, Furuyama M, Hashimoto T, et al. Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy. Clin Exp Nephrol. 2009;13:659–62.

    Article  CAS  PubMed  Google Scholar 

  18. Ieiri N, Hotta O, Taguma Y. Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy. Am J Kidney Dis. 2003;41:244–9.

    Article  PubMed  Google Scholar 

  19. Arai T, Yamashita S, Yamane M, et al. Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy. Atherosclerosis. 2003;169:293–9.

    Article  CAS  PubMed  Google Scholar 

  20. Kinomura M, Sugiyama H, Saito T, et al. A novel variant apolipoprotein E Okayama in a patient with lipoprotein glomerulopathy. Nephrol Dial Transplant. 2008;23:751–6.

    Article  CAS  PubMed  Google Scholar 

  21. Liao MT, Tsai IJ, Cheng HT, et al. A rare cause of childhood-onset nephrotic syndrome: lipoprotein glomerulopathy. Clin Nephrol. 2012;78:237–40.

    Article  CAS  PubMed  Google Scholar 

  22. Tokura T, Itano S, Kobayashi S, Kuwabara A, Fujimoto S, Horike H, Satoh M, Komai N, Tomita N, Matsunaga A, Saito T, Sasaki T, Kashihara N. A novel mutation ApoE2 Kurashiki (R158P) in a patient with lipoprotein glomerulopathy. J Atheroscler Thromb. 2011;18:536–41.

    Article  CAS  PubMed  Google Scholar 

  23. Hamatani H, Hiromura K, Kobatake K, et al. Successful treatment of lipoprotein glomerulopathy in a daughter and a mother using niceritrol. Clin Exp Nephrol. 2010;14:619–24.

    Article  PubMed  Google Scholar 

  24. Zhou Y, Kong X, Zhao P, et al. Peroxisome proliferator-activated receptor-α is renoprotective in doxorubicin-induced glomerular injury. Kidney Int. 2011;79:1302–11.

    Article  CAS  PubMed  Google Scholar 

  25. Park CW, Zhang Y, Zhang X, et al. PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int. 2006;69:1511–7.

    Article  CAS  PubMed  Google Scholar 

  26. Kono K, Kamijo Y, Hora K, et al. PPARα attenuates the proinflammatory response in activated mesangial cells. Am J Physiol Renal Physiol. 2009;296:F328–36.

    Article  CAS  PubMed  Google Scholar 

  27. Tanaka Y, Kume S, Araki S, et al. Fenofibrate, a PPARα agonist, has renoprotective effects in mice by enhancing renal lipolysis. Kidney Int. 2011;79:871–82.

    Article  CAS  PubMed  Google Scholar 

  28. Nishizawa Y, Shoji T, Nishitani H, et al. Hypertriglyceridemia and lowered apolipoprotein C-II/C-III ratio in uremia: effect of a fibric acid, clinofibrate. Kidney Int. 1993;44:1352–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Takao Saito, Professor of Fukuoka University School of Medicine, who performed the genetic analysis.

Author information

Authors and Affiliations

  1. Division of Nephrology, Department of Medicine, Yachiyo Medical Center, Tokyo Women’s Medical University, 477-96, Yachiyo, Chiba, Japan

    Ryosuke Usui & Minako Koike

  2. Division of Nephrology, Minami-Senju Hospital, Tokyo, Japan

    Masaki Takahashi

  3. Department of Medicine IV, Tokyo Women’s Medical University, Tokyo, Japan

    Kosaku Nitta

Authors
  1. Ryosuke Usui
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masaki Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kosaku Nitta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Minako Koike
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ryosuke Usui.

Ethics declarations

Informed consent

Informed consent for DNA sequencing was obtained from the patient.

Conflict of interest

The authors have declared that no Conflict of interest exists.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Usui, R., Takahashi, M., Nitta, K. et al. Five-year follow-up of a case of lipoprotein glomerulopathy with APOE Kyoto mutation. CEN Case Rep 5, 148–153 (2016). https://doi.org/10.1007/s13730-016-0214-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13730-016-0214-5

Keywords

Search

Navigation